600161 天坛生物
已收盘 10-31 15:00:00
资讯
新帖
简况
天坛生物(600161)2025年三季报简析:增收不增利
证券之星 · 10-25
天坛生物(600161)2025年三季报简析:增收不增利
天坛生物前三季度净利8.19亿元,同比下降22.16%
北京商报 · 10-24
天坛生物前三季度净利8.19亿元,同比下降22.16%
天坛生物(600161)披露下属企业药品临床试验进展,10月21日股价上涨0.42%
证券之星 · 10-21
天坛生物(600161)披露下属企业药品临床试验进展,10月21日股价上涨0.42%
天坛生物最新公告:近日正式开展人凝血酶原复合物Ⅲ期临床试验
证券之星 · 10-21
天坛生物最新公告:近日正式开展人凝血酶原复合物Ⅲ期临床试验
每周股票复盘:天坛生物(600161)成都蓉生获GMP符合性认证
证券之星 · 10-11
每周股票复盘:天坛生物(600161)成都蓉生获GMP符合性认证
天坛生物(600161)披露下属企业获得《药品GMP符合性检查告知书》及变更《药品生产许可证》公告,10月09日股价上涨1.05%
证券之星 · 10-09
天坛生物(600161)披露下属企业获得《药品GMP符合性检查告知书》及变更《药品生产许可证》公告,10月09日股价上涨1.05%
天坛生物最新公告:下属国药集团昆明血液制品有限公司获得“人纤维蛋白原”药物临床试验批准通知书
证券之星 · 09-30
天坛生物最新公告:下属国药集团昆明血液制品有限公司获得“人纤维蛋白原”药物临床试验批准通知书
每周股票复盘:天坛生物(600161)子公司获GMP符合性认证
证券之星 · 09-27
每周股票复盘:天坛生物(600161)子公司获GMP符合性认证
天坛生物(600161.SH)下属公司获药品GMP符合性检查告知书
智通财经 · 09-22
天坛生物(600161.SH)下属公司获药品GMP符合性检查告知书
每周股票复盘:天坛生物(600161)拟每股派现0.15元(含税)
证券之星 · 09-20
每周股票复盘:天坛生物(600161)拟每股派现0.15元(含税)
天坛生物(600161)披露2025年半年度权益分派实施公告,9月18日股价下跌0.05%
证券之星 · 09-18
天坛生物(600161)披露2025年半年度权益分派实施公告,9月18日股价下跌0.05%
每周股票复盘:天坛生物(600161)将召开2025年半年度业绩说明会
证券之星 · 09-13
每周股票复盘:天坛生物(600161)将召开2025年半年度业绩说明会
股市必读:天坛生物中报 - 第二季度单季净利润同比下降5.13%
证券之星 · 08-24
股市必读:天坛生物中报 - 第二季度单季净利润同比下降5.13%
每周股票复盘:天坛生物(600161)股东户数增加,净利润下降12.88%
证券之星 · 08-23
每周股票复盘:天坛生物(600161)股东户数增加,净利润下降12.88%
天坛生物(600161)2025年中报简析:增收不增利
证券之星 · 08-22
天坛生物(600161)2025年中报简析:增收不增利
盘前公告淘金:国药承诺5年内整合天坛生物与派林生物;特一药业、千方科技上半年净利润大增超10倍;中国石化拟5亿元-10亿元回购公司A股股份
金融界 · 08-22
盘前公告淘金:国药承诺5年内整合天坛生物与派林生物;特一药业、千方科技上半年净利润大增超10倍;中国石化拟5亿元-10亿元回购公司A股股份
天坛生物最新公告:国药集团及中国生物承诺解决与公司新增同业竞争问题
证券之星 · 08-21
天坛生物最新公告:国药集团及中国生物承诺解决与公司新增同业竞争问题
天坛生物:2025年上半年净利润6.33亿元,同比下降12.88%
金融界 · 08-21
天坛生物:2025年上半年净利润6.33亿元,同比下降12.88%
每周股票复盘:天坛生物(600161)注射用重组人凝血因子Ⅷ-Fc融合蛋白完成Ⅰ期临床试验
证券之星 · 08-16
每周股票复盘:天坛生物(600161)注射用重组人凝血因子Ⅷ-Fc融合蛋白完成Ⅰ期临床试验
天坛生物:持续深化生产精细化管理保障产品市场供应
证券之星 · 08-15
天坛生物:持续深化生产精细化管理保障产品市场供应
加载更多
公司概况
公司名称:
北京天坛生物制品股份有限公司
所属行业:
医药制造业
上市日期:
1998-06-16
主营业务:
北京天坛生物制品股份有限公司的主营业务是以健康人血浆、经特异免疫的健康人血浆为原材料和采用基因重组技术研发、生产血液制品,开展血液制品经营业务。公司的主要产品是人血白蛋白、静注人免疫球蛋白(pH4)、破伤风人免疫球蛋白、狂犬病人免疫球蛋白、乙型肝炎人免疫球蛋白、冻干静注乙型肝炎人免疫球蛋白(pH4)、人免疫球蛋白、组织胺人免疫球蛋白、人凝血酶原复合物、人凝血因子Ⅷ、人纤维蛋白原、注射用重组人凝血因子Ⅷ。
发行价格:
4.07
{"stockData":{"symbol":"600161","market":"SH","secType":"STK","nameCN":"天坛生物","latestPrice":18.43,"timestamp":1761894001000,"preClose":18.33,"halted":0,"volume":7638614,"delay":0,"changeRate":0.0055,"floatShares":1977000000,"shares":1977000000,"eps":0.6656,"marketStatus":"已收盘","change":0.1,"latestTime":"10-31 15:00:00","open":18.33,"high":18.45,"low":18.29,"amount":141000000,"amplitude":0.0087,"askPrice":18.43,"askSize":963,"bidPrice":18.42,"bidSize":762,"shortable":0,"etf":0,"ttmEps":0.6656,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1762133400000},"marketStatusCode":5,"adr":0,"adjPreClose":18.33,"symbolType":"stock","openAndCloseTimeList":[[1761874200000,1761881400000],[1761886800000,1761894000000]],"highLimit":20.16,"lowLimit":16.5,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1977371446,"isCdr":false,"pbRate":3.18,"roa":"--","peRate":27.689303,"roe":"7.16%","epsLYR":0.78,"committee":-0.08866,"marketValue":36443000000,"turnoverRate":0.0039,"status":0,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2025-11-03。","floatMarketCap":36443000000},"requestUrl":"/m/hq/s/600161","defaultTab":"news","newsList":[{"id":"2578833976","title":"天坛生物(600161)2025年三季报简析:增收不增利","url":"https://stock-news.laohu8.com/highlight/detail?id=2578833976","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578833976?lang=zh_cn&edition=full","pubTime":"2025-10-26 06:01","pubTimestamp":1761429673,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期天坛生物发布2025年三季报。根据财报显示,天坛生物增收不增利。截至本报告期末,公司营业总收入44.65亿元,同比上升9.62%,归母净利润8.19亿元,同比下降22.16%。按单季度数据看,第三季度营业总收入13.55亿元,同比上升9.96%,第三季度归母净利润1.86亿元,同比下降42.84%。本次财报公布的各项数据指标表现一般。去年的净利率为35.02%,算上全部成本后,公司产品或服务的附加值极高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102600001415.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","BK0082","600161","BK0028","BK0188","BK0185","BK0046","BK0168","BK0239"],"gpt_icon":0},{"id":"2577192655","title":"天坛生物前三季度净利8.19亿元,同比下降22.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577192655","media":"北京商报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577192655?lang=zh_cn&edition=full","pubTime":"2025-10-24 20:07","pubTimestamp":1761307620,"startTime":"0","endTime":"0","summary":"北京商报讯(记者丁宁)10月24日晚间,天坛生物(600161)发布2025年三季报显示,公司前三季度营业收入44.65亿元,同比增长9.62%;归属净利润8.19亿元,同比下降22.16%。天坛生物表示,报告期内,销售价格下降,同时受信用政策影响,信用减值损失增加,归属净利润下降。(文章来源:北京商报)\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-10-24/doc-infuyzvk6807746.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-10-24/doc-infuyzvk6807746.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["600161","BK0028","BK0185","BK0188","BK0010","BK0239","BK0168","BK0082","BK0046"],"gpt_icon":0},{"id":"2577871661","title":"天坛生物(600161)披露下属企业药品临床试验进展,10月21日股价上涨0.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577871661","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577871661?lang=zh_cn&edition=full","pubTime":"2025-10-21 22:32","pubTimestamp":1761057134,"startTime":"0","endTime":"0","summary":"截至2025年10月21日收盘,天坛生物报收于19.08元,较前一交易日上涨0.42%,最新总市值为377.28亿元。该股当日开盘19.01元,最高19.12元,最低18.96元,成交额达1.29亿元,换手率为0.34%。公司近日发布公告称,其下属国药集团武汉生物制药有限公司研制的“人凝血酶原复合物”已完成临床伦理审查及入组前准备工作,近日正式开展Ⅲ期临床试验。该产品后续仍需完成Ⅲ期临床试验、提交上市申请并经审评审批,存在不确定性,提醒投资者注意风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102100037139.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0168","BK0046","BK0010","BK0188","BK0239","BK0028","600161","BK0082"],"gpt_icon":0},{"id":"2577001823","title":"天坛生物最新公告:近日正式开展人凝血酶原复合物Ⅲ期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2577001823","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577001823?lang=zh_cn&edition=full","pubTime":"2025-10-21 17:40","pubTimestamp":1761039625,"startTime":"0","endTime":"0","summary":"天坛生物(600161.SH)公告称,公司下属国药集团武汉生物制药有限公司研制的人凝血酶原复合物已完成临床伦理审查、临床入组前准备等工作,于近日正式开展Ⅲ期临床试验。该产品主要用于治疗先天性和获得性凝血因子Ⅱ、Ⅶ、Ⅸ和Ⅹ缺乏症,包括血友病B、抗凝剂过量、维生素K缺乏症等。目前国内市场已有多家企业生产该产品,国际市场也有多家跨国企业生产。但该产品后续尚需完成Ⅲ期临床试验、提交药品上市许可申请等程序,存在诸多内外部不确定因素,敬请广大投资者注意投资风险。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102100027380.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0082","BK0168","BK0188","BK0028","600161","BK0239","BK0185","BK0010"],"gpt_icon":0},{"id":"2574579044","title":"每周股票复盘:天坛生物(600161)成都蓉生获GMP符合性认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2574579044","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574579044?lang=zh_cn&edition=full","pubTime":"2025-10-12 01:50","pubTimestamp":1760205022,"startTime":"0","endTime":"0","summary":"截至2025年10月10日收盘,天坛生物报收于19.36元,较上周的19.08元上涨1.47%。本周,天坛生物10月10日盘中最高价报19.38元。本周关注点公司公告汇总:成都蓉生获《药品GMP符合性检查告知书》,可扩大重组人凝血因子Ⅷ生产规模公司公告汇总天坛生物下属成都蓉生药业有限责任公司收到四川省药品监督管理局颁发的《药品GMP符合性检查告知书》及变更后的《药品生产许可证》。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101200000349.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0082","BK0239","BK0028","BK0185","BK0168","600161","BK0188","BK0010","BK0046"],"gpt_icon":0},{"id":"2574169361","title":"天坛生物(600161)披露下属企业获得《药品GMP符合性检查告知书》及变更《药品生产许可证》公告,10月09日股价上涨1.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2574169361","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574169361?lang=zh_cn&edition=full","pubTime":"2025-10-09 22:44","pubTimestamp":1760021061,"startTime":"0","endTime":"0","summary":"截至2025年10月9日收盘,天坛生物报收于19.28元,较前一交易日上涨1.05%,最新总市值为381.24亿元。该股当日开盘19.13元,最高19.31元,最低19.01元,成交额达2.5亿元,换手率为0.66%。公司近日发布公告称,其下属成都蓉生药业有限责任公司收到四川省药品监督管理局颁发的《药品GMP符合性检查告知书》和变更后的《药品生产许可证》。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025100900034716.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0168","600161","BK0239","BK0185","BK0046","BK0028","BK0010","BK0188","BK0082"],"gpt_icon":0},{"id":"2571310793","title":"天坛生物最新公告:下属国药集团昆明血液制品有限公司获得“人纤维蛋白原”药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2571310793","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2571310793?lang=zh_cn&edition=full","pubTime":"2025-09-30 17:19","pubTimestamp":1759223973,"startTime":"0","endTime":"0","summary":"天坛生物(600161.SH)公告称,公司下属企业国药集团昆明血液制品有限公司于2025年9月28日获得国家药品监督管理局签发的《药物临床试验批准通知书》,同意开展“人纤维蛋白原”临床试验。该产品主要用于先天性纤维蛋白原减少或缺乏症以及获得性纤维蛋白原减少症,包括严重肝脏损伤、肝硬化、弥散性血管内凝血、产后大出血等。产品规格为0.5g(25ml)/瓶,剂型为注射剂。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025093000028162.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0168","BK0028","BK0188","BK0082","BK0010","600161","BK0185","BK0239"],"gpt_icon":0},{"id":"2570894456","title":"每周股票复盘:天坛生物(600161)子公司获GMP符合性认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2570894456","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570894456?lang=zh_cn&edition=full","pubTime":"2025-09-28 04:01","pubTimestamp":1759003277,"startTime":"0","endTime":"0","summary":"截至2025年9月26日收盘,天坛生物报收于19.02元,较上周的19.37元下跌1.81%。本周,天坛生物9月22日盘中最高价报19.44元。本周关注点公司公告汇总:成都蓉生药业收到《药品GMP符合性检查告知书》,生产条件获监管认可。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092800001015.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600161","BK0188","BK0185","BK0168","BK0046","BK0028","BK0010","BK0082"],"gpt_icon":0},{"id":"2569785351","title":"天坛生物(600161.SH)下属公司获药品GMP符合性检查告知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2569785351","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569785351?lang=zh_cn&edition=full","pubTime":"2025-09-22 18:14","pubTimestamp":1758536076,"startTime":"0","endTime":"0","summary":"智通财经APP讯,天坛生物(600161.SH)公告,公司下属成都蓉生药业有限责任公司(简称“成都蓉生”)收到四川省药品监督管理局颁发的《药品GMP符合性检查告知书》,涉及车间为:重组产品生产车间。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1348000.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"天坛生物(600161.SH)下属公司获药品GMP符合性检查告知书","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0168","BK0028","BK0185","600161","BK0010","BK0188","BK0239","BK0082","BK0046"],"gpt_icon":0},{"id":"2569078243","title":"每周股票复盘:天坛生物(600161)拟每股派现0.15元(含税)","url":"https://stock-news.laohu8.com/highlight/detail?id=2569078243","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569078243?lang=zh_cn&edition=full","pubTime":"2025-09-21 02:39","pubTimestamp":1758393552,"startTime":"0","endTime":"0","summary":"截至2025年9月19日收盘,天坛生物报收于19.37元,较上周的19.73元下跌1.82%。本周,天坛生物9月18日盘中最高价报19.75元。本周关注点公司公告汇总:天坛生物拟每股派发现金红利0.15元(含税),股权登记日为2025年9月24日。本次利润分配以公司总股本1,977,371,446股为基数,共派发现金红利296,605,716.90元(含税)。分派对象为截至股权登记日在中国证券登记结算有限责任公司上海分公司登记在册的全体股东。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092100000509.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600161","BK0188","BK0010","BK0028","BK0082","BK0168","BK0185","BK0046"],"gpt_icon":0},{"id":"2568054004","title":"天坛生物(600161)披露2025年半年度权益分派实施公告,9月18日股价下跌0.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2568054004","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568054004?lang=zh_cn&edition=full","pubTime":"2025-09-18 22:35","pubTimestamp":1758206121,"startTime":"0","endTime":"0","summary":"截至2025年9月18日收盘,天坛生物报收于19.58元,较前一交易日下跌0.05%,最新总市值为387.17亿元。该股当日开盘19.58元,最高19.75元,最低19.44元,成交额达2.94亿元,换手率为0.76%。公司近日发布《2025年半年度权益分派实施公告》,宣布本次利润分配方案为每股派发现金红利0.15元(含税)。股权登记日为2025年9月24日,除权(息)日和现金红利发放日均为2025年9月25日。分派对象为截至股权登记日在中国证券登记结算有限责任公司上海分公司登记在册的全体股东。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091800037611.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0168","BK0010","BK0082","BK0185","BK0239","BK0188","BK0028","600161"],"gpt_icon":0},{"id":"2567133819","title":"每周股票复盘:天坛生物(600161)将召开2025年半年度业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2567133819","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567133819?lang=zh_cn&edition=full","pubTime":"2025-09-14 01:55","pubTimestamp":1757786112,"startTime":"0","endTime":"0","summary":"截至2025年9月12日收盘,天坛生物报收于19.73元,较上周的19.81元下跌0.4%。本周,天坛生物9月8日盘中最高价报20.17元。天坛生物当前最新总市值390.93亿元,在生物制品板块市值排名8/50,在两市A股市值排名454/5153。本周关注点公司公告汇总:天坛生物将于2025年9月16日召开2025年半年度业绩说明会。说明会期间,投资者可登录上证路演中心在线参与并提问。会后可通过该网站查看会议召开情况及主要内容。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091400000310.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0168","BK0046","BK0028","BK0239","BK0010","600161","BK0185","BK0188","BK0082"],"gpt_icon":0},{"id":"2562446264","title":"股市必读:天坛生物中报 - 第二季度单季净利润同比下降5.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562446264","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562446264?lang=zh_cn&edition=full","pubTime":"2025-08-25 04:20","pubTimestamp":1756066824,"startTime":"0","endTime":"0","summary":"截至2025年8月22日收盘,天坛生物报收于20.51元,下跌0.44%,换手率0.94%,成交量18.67万手,成交额3.82亿元。股本股东变化截至2025年6月30日,天坛生物股东户数为7.79万户,较3月31日增加3696户,增幅为4.98%。业绩披露要点天坛生物2025年中报显示,公司主营收入31.1亿元,同比上升9.47%;归母净利润6.33亿元,同比下降12.88%;扣非净利润6.18亿元,同比下降14.54%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082500000971.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600161"],"gpt_icon":0},{"id":"2561230593","title":"每周股票复盘:天坛生物(600161)股东户数增加,净利润下降12.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2561230593","media":"证券之星","labels":["shareholding","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561230593?lang=zh_cn&edition=full","pubTime":"2025-08-24 02:50","pubTimestamp":1755975019,"startTime":"0","endTime":"0","summary":"截至2025年8月22日收盘,天坛生物报收于20.51元,较上周的20.26元上涨1.23%。本周,天坛生物8月21日盘中最高价报20.68元。本周关注点股本股东变化:截至2025年6月30日公司股东户数为7.79万户,较3月31日增加3696.0户业绩披露要点:2025年中报显示归母净利润6.33亿元,同比下降12.88%公司公告汇总:拟向全体股东每10股派发现金股利1.5元(含税)股本股东变化近日天坛生物披露,截至2025年6月30日公司股东户数为7.79万户,较3月31日增加3696.0户,增幅为4.98%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082400000543.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600161"],"gpt_icon":0},{"id":"2561285668","title":"天坛生物(600161)2025年中报简析:增收不增利","url":"https://stock-news.laohu8.com/highlight/detail?id=2561285668","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561285668?lang=zh_cn&edition=full","pubTime":"2025-08-23 06:02","pubTimestamp":1755900171,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期天坛生物发布2025年中报。根据财报显示,天坛生物增收不增利。截至本报告期末,公司营业总收入31.1亿元,同比上升9.47%,归母净利润6.33亿元,同比下降12.88%。筹资活动产生的现金流量净额变动幅度为23.78%,原因:分配股利支出同比减少;与去年同期相比增加不满足终止确认的票据贴现。持有天坛生物最多的基金为国泰中证生物医药ETF,目前规模为35.26亿元,最新净值1.1295,较上一交易日上涨1.02%,近一年上涨38.26%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082300006096.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0082","BK0239","BK0010","BK0185","BK0028","BK0188","BK0046","600161","BK0168"],"gpt_icon":0},{"id":"2561410485","title":"盘前公告淘金:国药承诺5年内整合天坛生物与派林生物;特一药业、千方科技上半年净利润大增超10倍;中国石化拟5亿元-10亿元回购公司A股股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2561410485","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561410485?lang=zh_cn&edition=full","pubTime":"2025-08-22 08:23","pubTimestamp":1755822181,"startTime":"0","endTime":"0","summary":"【重要事项】兰石重装:投资2.07亿元建设青岛核电装备产能提升项目先导智能:已成功输出量产级固态电池整线方案,相关产品已陆续获得重复订单盛视科技:投资设立全资子公司,旨在将AI、人形机器人技术与潮玩创新结合泽璟制药:注射用ZG005、注射用ZGGS18与盐酸吉卡昔替尼片联用获得药物临床试验批准通知书天坛生物:国药集团及中国生物承诺解决与公司新增同业竞争问题长春高新:子公司注射用GenSci143注","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.jrj.com.cn/2025/08/22082352601206.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["000403","399300","159982","002728","600161","600028","002373"],"gpt_icon":0},{"id":"2561465336","title":"天坛生物最新公告:国药集团及中国生物承诺解决与公司新增同业竞争问题","url":"https://stock-news.laohu8.com/highlight/detail?id=2561465336","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561465336?lang=zh_cn&edition=full","pubTime":"2025-08-21 17:48","pubTimestamp":1755769710,"startTime":"0","endTime":"0","summary":"天坛生物(600161.SH)公告称,公司收到实际控制人国药集团及控股股东中国生物出具的承诺函,因中国生物收购派林生物21.03%股份导致与公司新增同业竞争,承诺在五年内通过包括资产置换、资产出售、资产注入、设立合资企业等方式解决同业竞争问题。同时承诺不新增与天坛生物主营业务构成竞争的业务,并公平对待下属控股企业。该承诺函自中国生物取得派林生物控制权之日起生效。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082100030205.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0082","BK0185","BK0188","BK0168","BK0239","BK0028","600161","BK0010"],"gpt_icon":0},{"id":"2561837463","title":"天坛生物:2025年上半年净利润6.33亿元,同比下降12.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2561837463","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561837463?lang=zh_cn&edition=full","pubTime":"2025-08-21 17:28","pubTimestamp":1755768483,"startTime":"0","endTime":"0","summary":"天坛生物公告,2025年上半年营业收入31.1亿元,同比增长9.47%。净利润6.33亿元,同比下降12.88%。公司拟以2025年6月末总股本19.77亿股为基数,向全体股东每10股派发现金股利1.5元(含税),分红总金额2.97亿元(含税)。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/08/21172852590098.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["600161"],"gpt_icon":0},{"id":"2560925437","title":"每周股票复盘:天坛生物(600161)注射用重组人凝血因子Ⅷ-Fc融合蛋白完成Ⅰ期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2560925437","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560925437?lang=zh_cn&edition=full","pubTime":"2025-08-17 03:29","pubTimestamp":1755372550,"startTime":"0","endTime":"0","summary":"截至2025年8月15日收盘,天坛生物报收于20.26元,较上周的20.43元下跌0.83%。本周,天坛生物8月12日盘中最高价报20.66元。天坛生物当前最新总市值400.62亿元,在生物制品板块市值排名8/50,在两市A股市值排名400/5152。产品在生产、上市销售前还需开展Ⅲ期临床试验,提交药品上市许可申请并通过国家药品监督管理局审批。本次完成Ⅰ期临床试验预计对公司近期业绩不会产生重大影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081700000468.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600161","BK0028","BK0185","BK0188","BK0010","BK0239","BK0168","BK0082","BK0046"],"gpt_icon":0},{"id":"2559913016","title":"天坛生物:持续深化生产精细化管理保障产品市场供应","url":"https://stock-news.laohu8.com/highlight/detail?id=2559913016","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2559913016?lang=zh_cn&edition=full","pubTime":"2025-08-15 17:48","pubTimestamp":1755251292,"startTime":"0","endTime":"0","summary":"证券之星消息,天坛生物08月15日在投资者关系平台上答复投资者关心的问题。公司无近年外汇进口人血白蛋白准确的官方数据。血液制品具有较强的资源属性,上游血浆采集量较大程度影响血液制品产量和增速,2024年,公司全年实现采集血浆约2781吨,公司持续深化生产精细化管理,严格执行生产计划,确保血浆应投尽投,产品应交尽交,保障产品市场供应。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081500034200.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","BK0082","600161","BK0028","BK0188","BK0185","BK0046","BK0168","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1761971330243,"stockEarnings":[{"period":"1week","weight":-0.0346},{"period":"1month","weight":-0.0341},{"period":"3month","weight":-0.0745},{"period":"6month","weight":-0.0218},{"period":"1year","weight":-0.1334},{"period":"ytd","weight":-0.0891}],"compareEarnings":[{"period":"1week","weight":0.0011},{"period":"1month","weight":0.0185},{"period":"3month","weight":0.1109},{"period":"6month","weight":0.2061},{"period":"1year","weight":0.2058},{"period":"ytd","weight":0.1799}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京天坛生物制品股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"79044人(较上一季度增加1.50%)","perCapita":"25016股","listingDate":"1998-06-16","address":"北京市大兴区北京经济技术开发区博兴二路6号院8号楼521室","registeredCapital":"197737万元","survey":" 北京天坛生物制品股份有限公司的主营业务是以健康人血浆、经特异免疫的健康人血浆为原材料和采用基因重组技术研发、生产血液制品,开展血液制品经营业务。公司的主要产品是人血白蛋白、静注人免疫球蛋白(pH4)、破伤风人免疫球蛋白、狂犬病人免疫球蛋白、乙型肝炎人免疫球蛋白、冻干静注乙型肝炎人免疫球蛋白(pH4)、人免疫球蛋白、组织胺人免疫球蛋白、人凝血酶原复合物、人凝血因子Ⅷ、人纤维蛋白原、注射用重组人凝血因子Ⅷ。","listedPrice":4.07},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.5","shortVersion":"4.35.5","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"天坛生物(600161)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供天坛生物(600161)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"天坛生物,600161,天坛生物股票,天坛生物股票老虎,天坛生物股票老虎国际,天坛生物行情,天坛生物股票行情,天坛生物股价,天坛生物股市,天坛生物股票价格,天坛生物股票交易,天坛生物股票购买,天坛生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"天坛生物(600161)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供天坛生物(600161)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}